Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.52 |
| ▸ | CES1 | P23141 | 7/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001602 | 1.00 | CES2 (0.52) | CES2CES1TRPM8PDE2ARIPK1 | |
| SCHEMBL4099522 | 1.00 | CES2 (0.52) | CES2CES1TRPM8PDE2ARIPK1 | |
| SCHEMBL9945882 | 0.81 | CES2 (0.50) | CES2CES1TRPM8RIPK1 | |
| SCHEMBL25109665 | 0.80 | TRPM8 (0.40) | CES2CES1TRPM8PDE2AKCNH2 | |
| SCHEMBL24458099 | 0.80 | CES2 (0.34) | CES2CES1PDE2AKCNH2MEN1 | |
| SCHEMBL3459934 | 0.79 | CES2 (0.46) | CES2CES1TRPM8 | |
| SCHEMBL28266437 | 0.79 | CES2 (0.53) | CES2CES1TRPM8 | |
| SCHEMBL2000512 | 0.79 | CES2 (0.33) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL13265069 | 0.78 | CES2 (0.37) | CES2CES1PDE2AKCNH2ADRB2 | |
| SCHEMBL6744704 | 0.78 | CES2 (0.37) | CES2CES1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097101-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112465-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | CES2 1375/4885CES1 851/4885TRPM8 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.